ERC Starting Grant · 2024
Gene therapies aim to cure genetic diseases by modifying the DNA blueprint. An ideal gene therapy should be durable, safe, and efficient, which often requires integration of large therapeutic DNA cargo at precise genomic locations. Advanced DNA editors with programmable specificities, such as the CRISPR technology, are limited by the nuclease-based mechanism and poor efficiency of large DNA insertions. Increased efficiency, specificity and precision of large edits are required to address a broad therapeutic space. Tyrosine recombinases (YRs) efficiently rearrange large DNA segments without the pitfalls of nuclease-based editors, but with an important caveat – rational reprogramming of their…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.